Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Generation 2.5 Antisense Oligonucleotides Targeting the Androgen Receptor and Its Splice Variants Suppress Enzalutamide-Resistant Prostate Cancer Cell Growth

30 Jan 2015

Abstract excerpt

PURPOSE: Enzalutamide (ENZ) is a potent androgen receptor (AR) antagonist with activity in castration-resistant prostate cancer (CRPC); however, progression to ENZ-resistant (ENZ-R) CRPC frequently occurs with rising serum PSA levels, implicating AR full-length (ARFL) or variants (AR-Vs) in disease progression. EXPERIMENTAL DESIGN: To define functional roles of ARFL and AR-Vs in ENZ-R CRPC, we designed 3...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Estrogen and related hormone effects
Share to Prostate Cancer Diagnosis and Treatment
Share to Prostate Cancer Treatment and Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25634993
DOI: 10.1158/1078-0432.ccr-14-1108

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Generation 2.5 Antisense Oligonucleotides Targeting the Androgen Receptor and Its Splice Variants Suppress Enzalutamide-Resistant Prostate Cancer Cell GrowthPMID 25634993Read ↗

Inhibition of Galectin-1 and androgen receptor axis enhances enzalutamide treatment in enzalutamide resistant prostate cancerSemantic proximity Read ↗

Epigenetic Reprogramming with Antisense Oligonucleotides Enhances the Effectiveness of Androgen Receptor Inhibition in Castration-Resistant Prostate CancerSemantic proximity Read ↗

Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responsesSemantic proximity Read ↗

Targeting Androgen Receptor Activation Function-1 with EPI to Overcome Resistance Mechanisms in Castration-Resistant Prostate Cancer.Semantic proximity Read ↗

Identification of genes required for enzalutamide resistance in castration-resistant prostate cancer cells <i>in vitro</i>Semantic proximity Read ↗

Non-drug efflux function of ABCC5 promotes enzalutamide resistance in castration-resistant prostate cancer via upregulation of P65/AR-V7Semantic proximity Read ↗

Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamideSemantic proximity Read ↗

Understanding the development of enzalutamide resistance based on a functional single-cell approachSemantic proximity Read ↗

Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).Semantic proximity Read ↗

Androgen receptor variants: RNA-based mechanisms and therapeutic targetsSemantic proximity Read ↗

Non-coding RNAs in enzalutamide resistance of castration-resistant prostate cancerSemantic proximity Read ↗

Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variantSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.